KRAS and pancreatic neoplasm: Since Kras mutations are found in more than 95% of pancreatic cancers in human, we hypothesized that sustained inflammation due to the lack of SIRT2 activity accumulates a cell population carrying Kras mutations that originally existed in the pancreas through the disruption-regeneration cycles during pancreatitis.